Table S1.
Patient baseline characteristics according to region
| USA
|
EU5
|
|||||
|---|---|---|---|---|---|---|
| Asthma (n=2,157) |
COPD (n=1,632) |
ACOS (n=169) |
Asthma (n=6,885) |
COPD (n=5,487) |
ACOS (n=354) |
|
| Demographics | ||||||
| Age, years | 42.5 | 67.4 | 64.5 | 41.8 | 65.5 | 65.5 |
| Male, % | 40.1 | 55.2 | 48.5 | 46.0 | 69.2 | 54.7 |
| BMI, kg/m2 | 28.6 | 27.8 | 29.5 | 25.2 | 26.3 | 26.6 |
| Never smoker, % | 79.2 | 2.0 | 4.2 | 67.3 | 2.9 | 6.1 |
| Comorbidities, % | ||||||
| Elevated cholesterol | 16.9 | 39.5 | 41.6 | 8.5 | 25.5 | 23.4 |
| Hypertension | 26.1 | 67.4 | 61.5 | 17.9 | 56.2 | 53.8 |
| Arthritis | 9.0 | 26.4 | 28.6 | 3.1 | 8.4 | 10.8 |
| Diabetes | 7.7 | 17.7 | 28.0 | 5.5 | 17.8 | 19.0 |
| GERD | 18.0 | 22.8 | 23.6 | 8.2 | 10.5 | 16.9 |
| Treatment, % | ||||||
| LABA alone | 0.1 | 1.5 | 2.4 | 1.5 | 6.6 | 3.4 |
| ICS alone | 14.8 | 3.5 | 7.7 | 15.7 | 2.6 | 2.3 |
| LAMA alone | 0.5 | 20.5 | 8.3 | 0.3 | 19.0 | 7.4 |
| ICS/LABA alone | 34.1 | 24.2 | 23.8 | 43.8 | 14.5 | 20.7 |
| ICS/LABA + LAMA | 0.7 | 31.6 | 20.2 | 1.7 | 32.1 | 36.9 |
| Symptoms, % | ||||||
| SOB | 16.7 | 28.5 | 31.4 | 15.0 | 27.9 | 31.2 |
| SOB during exertion | 45.6 | 66.6 | 66.9 | 44.7 | 73.0 | 77.3 |
| Wheezing | 39.0 | 34.5 | 49.1 | 27.7 | 28.3 | 38.5 |
| Exacerbationsa in last 12 months, n | 0.9 | 1.5 | 2.1 | 0.9 | 1.8 | 2.4 |
Note:
a
Exacerbations defined as physician-confirmed worsening of symptoms beyond day-to-day variation.
Abbreviations: ACOS, asthma and COPD overlap syndrome; COPD, chronic obstructive pulmonary disease; EU5, Spain, Italy, France, Germany, and the UK; GERD, gastroesophageal reflux disease; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; SOB, shortness of breath.